[144] CareDx, Inc. SEC Filing

Rhea-AI Filing Summary

CareDx, Inc. insider Jeffrey Novack has filed a Form 144 notice to sell company stock. The filing covers a proposed sale of 4,441 shares of CareDx common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $90,685.22 and 51,432,639 shares of common stock outstanding.

The shares to be sold were acquired on 02/01/2026 via 2,591 restricted stock units and 1,850 performance stock units from the issuer, both settled on 02/01/2026. Over the past three months, Form 144 discloses additional 10b5-1 sales for Jeffrey Novack totaling 7,293 shares on 12/04/2025 and 2,688 shares on 11/07/2025, with gross proceeds of $139,804.74 and $41,722.87, respectively.

Insights

Insider trading and corporate governance analyst

Routine Form 144 shows modest planned sales under Rule 10b5-1.

The notice details a planned sale of 4,441 CareDx common shares with an indicated market value of $90,685.22, against 51,432,639 shares outstanding. The securities come from recently vested restricted stock units and performance stock units dated 02/01/2026.

The document also lists prior three‑month 10b5‑1 sales of 7,293 and 2,688 shares, with gross proceeds of $139,804.74 and $41,722.87. The signatory represents they are not aware of undisclosed material adverse information, consistent with Rule 144 and Rule 10b5‑1 requirements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4441	90685.22	51432639	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Units	Issuer			2591	02/01/2026	N/A
Common	02/01/2026	Performance Stock Units	Issuer			1850	02/01/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JEFFREY NOVACK 8000 Marina Boulevard, 4th Floor Brisbane CA 94005	Common	12/04/2025	7293	139804.74
10b5-1 Sales for JEFFREY NOVACK 8000 Marina Boulevard, 4th Floor Brisbane CA 94005	COMMON	11/07/2025	2688	41722.87

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CareDx (CDNA) Form 144 filing by Jeffrey Novack disclose?

The Form 144 discloses a proposed sale of 4,441 CareDx common shares by or for Jeffrey Novack. These shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an indicated aggregate market value of $90,685.22 and 51,432,639 shares outstanding.

How many CareDx (CDNA) shares are planned to be sold under this Form 144?

The filing shows an intent to sell 4,441 shares of CareDx common stock. The planned sale, routed through Morgan Stanley Smith Barney LLC, has an aggregate market value of $90,685.22 based on the figures disclosed in the notice for Rule 144 compliance.

How were the CareDx (CDNA) shares in the Form 144 acquired?

The shares were acquired on February 1, 2026 through equity awards from the issuer. The filing lists 2,591 shares from restricted stock units and 1,850 shares from performance stock units, both dated 02/01/2026, with settlement and payment also recorded on that date as non‑cash awards.

What prior CareDx (CDNA) stock sales are reported in the last three months?

The notice reports two prior 10b5‑1 sales for Jeffrey Novack in the last three months. On 12/04/2025, 7,293 common shares were sold for gross proceeds of $139,804.74, and on 11/07/2025, 2,688 common shares were sold for gross proceeds of $41,722.87.

What is the total number of CareDx (CDNA) shares outstanding mentioned in the Form 144?

The filing states that 51,432,639 shares of CareDx common stock are outstanding. This figure provides context for evaluating the relative size of the 4,441 shares covered by the planned sale disclosed in the Form 144 notice under SEC Rule 144.

Does the CareDx (CDNA) Form 144 mention Rule 10b5-1 trading plans?

Yes. The three‑month sales section specifically identifies the past transactions as “10b5‑1 Sales for JEFFREY NOVACK.” The signature section also references Rule 10b5‑1 plans and representations about not knowing undisclosed material adverse information when trades or plans are established.